How do some haemophiliacs develop inhibitors?

被引：28

作者：

Vermylen, J

机构：

[1] Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium

[2] Catholic Univ Louvain, Div Bleeding & Vasc Disorders, B-3000 Louvain, Belgium

来源：

HAEMOPHILIA | 1998年 / 4卷 / 04期

关键词：

haemophilia; factor VIII inhibitors; major histocompatibility class II; factor VIII mutations; factor VIII products; immunosuppressor mechanisms;

D O I：

10.1046/j.1365-2516.1998.440538.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The purpose of this presentation is to concentrate on three issues: Is there an explanation for the large difference in reported incidence rates of inhibitor formation in haemophiliacs? Why do not all severe patients develop inhibitors? And how on the contrary do some patients with mild haemophilia develop inhibitors?.

引用

页码：538 / 542

页数：5

共 28 条

[1] FREQUENCY OF INHIBITOR DEVELOPMENT IN HEMOPHILIACS TREATED WITH LOW-PURITY FACTOR-VIII [J].

ADDIEGO, J ;

KASPER, C ;

ABILDGAARD, C ;

HILGARTNER, M ;

LUSHER, J ;

GLADER, B ;

ALEDORT, L .

LANCET, 1993, 342 (8869) :462-464

[2] NATURAL ANTIBODIES TO FACTOR-VIII (ANTI-HEMOPHILIC FACTOR) IN HEALTHY-INDIVIDUALS [J].

ALGIMAN, M ;

DIETRICH, G ;

NYDEGGER, UE ;

BOIELDIEU, D ;

SULTAN, Y ;

KAZATCHKINE, MD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (09) :3795-3799

[3] FACTOR-VIII GENE INVERSIONS IN SEVERE HEMOPHILIA-A - RESULTS OF AN INTERNATIONAL CONSORTIUM STUDY [J].

ANTONARAKIS, SE ;

ROSSITER, JP ;

YOUNG, M ;

HORST, J ;

DEMOERLOOSE, P ;

SOMMER, SS ;

KETTERLING, RP ;

KAZAZIAN, HH ;

NEGRIER, C ;

VINCIGUERRA, C ;

GITSCHIER, J ;

GOOSSENS, M ;

GIRODON, E ;

GHANEM, N ;

PLASSA, F ;

LAVERGNE, JM ;

VIDAUD, M ;

COSTA, JM ;

LAURIAN, Y ;

LIN, SW ;

LIN, SR ;

SHEN, MC ;

LILLICRAP, D ;

TAYLOR, SAM ;

WINDSOR, S ;

VALLEIX, SV ;

NAFA, K ;

SULTAN, Y ;

DELPECH, M ;

VNENCAKJONES, CL ;

PHILLIPS, JA ;

LJUNG, RCR ;

KOUMBARELIS, E ;

GIALERAKI, A ;

MANDALAKI, T ;

JENKINS, PV ;

COLLINS, PW ;

PASI, KJ ;

GOODEVE, A ;

PEAKE, I ;

PRESTON, FE ;

SCHWARTZ, M ;

SCHEIBEL, E ;

INGERSLEV, J ;

COOPER, DN ;

MILLAR, DS ;

KAKKAR, VV ;

GIANNELLI, F ;

NAYLOR, JA ;

TIZZANO, EF .

BLOOD, 1995, 86 (06) :2206-2212

[4]

BARROWFCLIFFE TW, 1997, THROMB HAEMOST S, V576

[5]

BRAY GL, 1994, BLOOD, V83, P2428

[6]

BRIET E, 1994, THROMB HAEMOSTASIS, V72, P162

[7] INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].

EHRENFORTH, S ;

KREUZ, W ;

SCHARRER, I ;

LINDE, R ;

FUNK, M ;

GUNGOR, T ;

KRACKHARDT, B ;

KORNHUBER, B .

LANCET, 1992, 339 (8793) :594-598

[8] HEALTHY-SUBJECTS PRODUCE BOTH ANTI-FACTOR-VIII AND SPECIFIC ANTIIDIOTYPIC ANTIBODIES [J].

GILLES, JG ;

SAINTREMY, JMR .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (04) :1496-1505

[9] Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A [J].

Gilles, JG ;

Desqueper, B ;

Lenk, H ;

Vermylen, J ;

SaintRemy, JM .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (06) :1382-1388

[10]

Gilles JGG, 1997, THROMB HAEMOSTASIS, V77, P938

← 1 2 3 →